← All trials
NCT05110001
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Oct 31, 2024
- Completion date
- Jan 31, 2025
- First posted
- Nov 5, 2021
- Last posted
- Nov 5, 2021
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- Stanford UniversityStudy director
- Aravind Eye HospitalCollaborator
- Stanford UniversityOverall official - principal investigator
- Stanford UniversityCollaborator
- University of California, San FranciscoSponsor investigator
- National Eye Institute (NEI)Collaborator
- University of California, San FranciscoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.